Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
The Early-Onset Parkinson's Disease and Synucleinopathies Lab at Mayo Clinic is breaking new ground in the study of early-onset Parkinson's disease and related neurodegenerative disorders through these focus areas:
Clinical alphasynucleinopathies epidemiology timeline
Shows the preclinical epidemiology factors of alphasynucleinopathies of neurodegeneration and the mechanisms that influence the staging system for Lewy body disorders.
Clinical alphasynucleinopathies timeline
Shows the preclinical timeline for alphasynucleinopathies that influences the unified staging system for Lewy body disorders.
Cumulative incidence of mortality and sex difference among individuals ages 50 and younger who met criteria for parkinsonism. Source: Camerucci E, et al. Early-onset parkinsonism and early-onset Parkinson's disease: A population-based study (2010-2015). Journal of Parkinson's Disease. 2021; doi:10.3233/JPD-202464.
Patient symptom-onset timeline
Patient's timeline of cardinal motor symptoms onset relative to early-onset Parkinson's disease diagnosis before 55 years of age. Source: Camerucci E, et al. Early-onset parkinsonism and early-onset Parkinson's disease: A population-based study (2010-2015). Journal of Parkinson's Disease. 2021; doi:10.3233/JPD-202464.
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.